Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Alaunos Therapeutics, Inc.

Market Cap 52.32L 45.72L 42.29L 39.47L 74.09L 49Cr 74.64L 5.03Cr 1.96Cr 24Cr 1.96Cr 1.92Cr 84Cr P/E 2024
-0.65x
P/E 2025 -1.47x
Enterprise Value 38.47L 33.61L 31.09L 29.02L 54.48L 36Cr 54.88L 3.69Cr 1.44Cr 18Cr 1.44Cr 1.41Cr 62Cr EV / Sales 2024
19,59,38,500x
EV / Sales 2025 1,16,47,61,400x
Free-Float
85.97%
Yield 2024 *
-
Yield 2025 -
1 day+0.47%
1 week-5.26%
Current month-24.21%
1 month-10.74%
3 months-32.92%
6 months-40.50%
Current year-33.13%
1 week 2.15
Extreme 2.15
2.25
1 month 1.92
Extreme 1.92
3.09
Current year 1.92
Extreme 1.92
4.04
1 year 1.67
Extreme 1.67
6.2
3 years 1.31
Extreme 1.3137
78
5 years 1.31
Extreme 1.3137
601.5
10 years 1.31
Extreme 1.3137
1,182
Manager TitleAgeSince
Chief Executive Officer 63 02/07/2025
Director of Finance/CFO 41 22/02/2025
Director TitleAgeSince
Director/Board Member 57 16/12/2020
Chairman 63 22/09/2023
Director/Board Member 72 05/02/2021
Date Insider Type Main position Quantity % Market Cap.
12/06Free

Chief Executive Officer

7,761 0.3178%
22/05Free

Chief Executive Officer

3,700 0.1556%
29/04Free

Director

6,032 0.2703%
Change 5-day change 1-year change 3-year change Capi.($)
+0.47%-5.26%-49.65%-96.80% 52.08L
+2.87%+4.57%+68.97%+119.22% 5.52TCr
+4.00%+7.51%+63.67%+68.77% 4.58TCr
-0.77%-0.67%-15.34%-15.95% 2.3TCr
+2.93%+1.17%-3.97%+384.78% 2.08TCr
+2.80%+5.26%+28.98%-16.29% 1.63TCr
+1.16%+3.86%+20.23%-36.42% 1.54TCr
-1.08%-3.11%+27.20%+158.30% 1.3TCr
+3.30%+15.02%+133.24%+273.89% 1.24TCr
+3.87%-4.18%+24.42% - 1.24TCr
Average +1.96%+2.67%+29.77%+93.28% 2.14TCr
Weighted average by Cap. +2.44%+3.92%+43.79%+108.97%

Financials

2024 2025
Net sales 0.01 0.01 0.01 0.01 0.01 0.95 0.01 0.1 0.04 0.46 0.04 0.04 1.61 0 0 0 0 0.01 0.47 0.01 0.05 0.02 0.23 0.02 0.02 0.81
Net income -46.79L -40.89L -37.82L -35.3L -66.27L -44Cr -66.75L -4.49Cr -1.75Cr -22Cr -1.76Cr -1.72Cr -76Cr -41.76L -36.49L -33.75L -31.5L -59.14L -39Cr -59.57L -4.01Cr -1.56Cr -19Cr -1.57Cr -1.53Cr -67Cr
Net Debt -10.91L -10L -9L -8L -15.45L -10Cr -15.56L -1.05Cr -40.77L -5.07Cr -40.96L -40.07L -18Cr -13.85L -12.1L -11.19L -10.45L -19.61L -13Cr -19.76L -1.33Cr -51.76L -6.44Cr -52L -50.87L -22Cr
Logo Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.
Employees
1
Date Price Change Volume
22/26/22 2.160 $ +0.47% 1,517
18/26/18 2.150 $ -3.15% 16,127
17/26/17 2.220 $ -0.89% 1,332
16/26/16 2.240 $ -1.75% 5,148

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRT Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!